ReviewRSC advances2022
Recent advancements in the multicomponent synthesis of heterocycles integrated with a pyrano[2,3-
Review in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Bioinspired NiCoODiscover nano · 2026Article
- Design and application of a magnetically recoverable citric acid-functionalized graphene oxide nanocomposite for ultrasound-assisted green synthesis of naphthopyrimidines.Scientific reports · 2026Article
- Synthesis of pyrano-pyrimidines: recent advances in catalysis by magnetically recoverable nanocatalysts.Molecular diversity · 2024Review
- Developments of pyridodipyrimidine heterocycles and their biological activities.Molecular diversity · 2024Review
- Synthetic strategies of heterocycle-integrated pyridopyrimidine scaffolds supported by nano-catalysts.RSC advances · 2023Review
- Importance of Hybrid Catalysts toward the Synthesis of 5ACS omega · 2023Review
- Recent progress in the chemistry of β-aminoketones.RSC advances · 2022Review
- Insights into the recent progress in the medicinal chemistry of pyranopyrimidine analogs.RSC medicinal chemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterocyclic compounds incorporated with a pyranopyrimidine skeleton have received substantial consideration owing to their privileged, and intelligible biodiversity. Accordingly, this review highlights the multicomponent synthetic routes adopted to prepare heterocyclic compounds incorporated with the pyrano[2,3-
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.